JP2022536408A - アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法 - Google Patents

アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法 Download PDF

Info

Publication number
JP2022536408A
JP2022536408A JP2022515975A JP2022515975A JP2022536408A JP 2022536408 A JP2022536408 A JP 2022536408A JP 2022515975 A JP2022515975 A JP 2022515975A JP 2022515975 A JP2022515975 A JP 2022515975A JP 2022536408 A JP2022536408 A JP 2022536408A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
aldh2
alcohol
acetaldehyde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536408A5 (https=
JPWO2020237172A5 (https=
Inventor
ケイ.ワイ. ジャン、エドワード
Original Assignee
イーケイワイジェイ コンサルティング ツー、エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーケイワイジェイ コンサルティング ツー、エルエルシー filed Critical イーケイワイジェイ コンサルティング ツー、エルエルシー
Publication of JP2022536408A publication Critical patent/JP2022536408A/ja
Publication of JP2022536408A5 publication Critical patent/JP2022536408A5/ja
Publication of JPWO2020237172A5 publication Critical patent/JPWO2020237172A5/ja
Priority to JP2025034659A priority Critical patent/JP2025093991A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2022515975A 2019-05-23 2020-05-22 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法 Pending JP2022536408A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025034659A JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852000P 2019-05-23 2019-05-23
US62/852,000 2019-05-23
PCT/US2020/034273 WO2020237172A1 (en) 2019-05-23 2020-05-22 Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025034659A Division JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022536408A true JP2022536408A (ja) 2022-08-15
JP2022536408A5 JP2022536408A5 (https=) 2023-05-08
JPWO2020237172A5 JPWO2020237172A5 (https=) 2023-05-08

Family

ID=73458156

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515975A Pending JP2022536408A (ja) 2019-05-23 2020-05-22 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法
JP2025034659A Pending JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025034659A Pending JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Country Status (7)

Country Link
US (1) US20220226286A1 (https=)
EP (1) EP3973030A4 (https=)
JP (2) JP2022536408A (https=)
KR (1) KR20220012903A (https=)
CN (2) CN119909065A (https=)
TW (1) TW202110437A (https=)
WO (1) WO2020237172A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102879756B1 (ko) 2022-11-11 2025-11-12 대한민국 이상지질혈증 예측 또는 진단용 snp 마커 및 이의 용도
KR102893400B1 (ko) 2022-11-21 2025-12-02 대한민국 당뇨병 예측 또는 진단용 hectd4 snp 마커 및 이의 용도

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6468319A (en) * 1987-09-09 1989-03-14 Nonogawa Shoji Yk Anti-inflammatory
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
JP2002542282A (ja) * 1999-04-22 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ 栄養補助食品または薬物として有用な、カルニチンおよびリン酸イノシトール含有組成物
JP2003519173A (ja) * 1999-12-30 2003-06-17 アンシル ファーマシューティカルズ,インコーポレイテッド 薬学的製剤用臭気マスキングコーティング
WO2007017139A1 (en) * 2005-07-29 2007-02-15 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP2011051942A (ja) * 2009-09-03 2011-03-17 Glovia:Kk 認知症治療薬
WO2011043365A1 (ja) * 2009-10-07 2011-04-14 学校法人武庫川学院 遺伝子型判定方法
JP2013512930A (ja) * 2009-12-07 2013-04-18 ラプター セラピューティックス インコーポレイテッド 4−メチルピラゾール製剤
JP2013536238A (ja) * 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法
WO2016042205A1 (en) * 2014-09-15 2016-03-24 Biohit Oyj Preparations for treatment and prevention of alcohol flushing and alcohol-induced hypersensitivity reactions
WO2018091609A1 (en) * 2016-11-17 2018-05-24 Amalicon Holding Ag Formulation comprising 4-methylpyrazole

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW271400B (https=) * 1992-07-30 1996-03-01 Pfizer
KR20090117950A (ko) * 2007-03-08 2009-11-16 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6468319A (en) * 1987-09-09 1989-03-14 Nonogawa Shoji Yk Anti-inflammatory
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
JP2002542282A (ja) * 1999-04-22 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ 栄養補助食品または薬物として有用な、カルニチンおよびリン酸イノシトール含有組成物
JP2003519173A (ja) * 1999-12-30 2003-06-17 アンシル ファーマシューティカルズ,インコーポレイテッド 薬学的製剤用臭気マスキングコーティング
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP2009516639A (ja) * 2005-07-29 2009-04-23 ティーマ ファウンデーション アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物
WO2007017139A1 (en) * 2005-07-29 2007-02-15 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
JP2011051942A (ja) * 2009-09-03 2011-03-17 Glovia:Kk 認知症治療薬
WO2011043365A1 (ja) * 2009-10-07 2011-04-14 学校法人武庫川学院 遺伝子型判定方法
JP2013512930A (ja) * 2009-12-07 2013-04-18 ラプター セラピューティックス インコーポレイテッド 4−メチルピラゾール製剤
JP2013536238A (ja) * 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法
WO2016042205A1 (en) * 2014-09-15 2016-03-24 Biohit Oyj Preparations for treatment and prevention of alcohol flushing and alcohol-induced hypersensitivity reactions
JP2017527595A (ja) * 2014-09-15 2017-09-21 ビオヒット・ユルキネン・オサケユキテュアBiohit Oyj アルコールフラッシング反応およびアルコール誘発性過敏反応の治療および予防用製剤
WO2018091609A1 (en) * 2016-11-17 2018-05-24 Amalicon Holding Ag Formulation comprising 4-methylpyrazole

Also Published As

Publication number Publication date
WO2020237172A1 (en) 2020-11-26
JP2025093991A (ja) 2025-06-24
CN114144493A (zh) 2022-03-04
US20220226286A1 (en) 2022-07-21
KR20220012903A (ko) 2022-02-04
TW202110437A (zh) 2021-03-16
EP3973030A1 (en) 2022-03-30
EP3973030A4 (en) 2023-05-31
CN119909065A (zh) 2025-05-02

Similar Documents

Publication Publication Date Title
US20190231766A1 (en) Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US9925174B2 (en) Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
AU2004258984B2 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
JP2025093991A (ja) アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法
CN109890366B (zh) 治疗心血管疾病的组合药物及其制备和使用方法
JP2025004090A (ja) 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン
TW201919622A (zh) 高劑量戊苯那嗪(valbenazine)調配物及組合物、方法以及相關套組
JP7727543B2 (ja) ホスホジエステラーゼ阻害剤を含有する放出調節錠剤製剤
CN102802418A (zh) 用于治疗肌萎缩性侧索硬化的组合物和方法
US20130150346A1 (en) Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
JP2022521233A (ja) 桂皮酸を含む組成物及びその使用方法
TWI777059B (zh) 肌肉減少症之預防劑及治療劑
JP5101306B2 (ja) 糖尿病治療剤
US20050182097A1 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
TW200920348A (en) Combination of picotamide with nafronyl
CN100431526C (zh) 一种酸敏感型药物的快速崩解片剂
CN110623955A (zh) Wnk激酶抑制剂在预防和/或治疗高原病中的用途
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
JP6707471B2 (ja) ピロールカルボキサミドの固形組成物
JP2024540241A (ja) 治療上の使用のためのアンブロキソールの修飾形態
KR20250123927A (ko) 간질성 폐 질환을 치료하기 위한 lpa1 길항제
HK40111138A (zh) 含有非索非那定的组合物
MXPA06005084A (en) Combination of proton pump inhibitor and sleep aid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230424

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241105